Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17713350 | 1.00 | LTA4H (0.52) | LTA4HLNPEPERAP2METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL4634588 | 1.00 | LTA4H (0.52) | LTA4HLNPEPERAP2METAP2METAP1 | |
| SCHEMBL1841055 | 0.98 | LTA4H (0.53) | LTA4HLNPEPERAP2METAP2METAP1 | |
| SCHEMBL5019109 | 0.98 | LTA4H (0.53) | LTA4HLNPEPERAP2METAP2METAP1 | |
| SCHEMBL276649 | 0.98 | LTA4H (0.53) | LTA4HLNPEPERAP2METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL5758683 | 0.90 | GRIK1 (0.54) | LTA4HKMT2A | |
| Trifluoroacetic Acid SCHEMBL7023585 | 0.90 | LTA4H (0.47) | LTA4HLNPEPERAP2METAP2METAP1 | |
| SCHEMBL1279303 | 0.89 | GRIK1 (0.55) | LTA4HKMT2A | |
| SCHEMBL7274943 | 0.89 | GRIK1 (0.55) | LTA4HKMT2A | |
| SCHEMBL2523775 | 0.87 | LTA4H (0.50) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034112-A1 | IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | UNIV YALE (US) | 2025-01-30 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-9901571-B2 | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3212648-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc. (JP) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016067638-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-05-06 | — | — | WO | disclosed |
| WO-2008104756-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE | SERENTIS LIMITED (GB) | 2008-09-04 | — | — | WO | disclosed |
| EP-1931624-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | Serentis Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1140709-A | Substituted N- (indole-2-carbonyl) -beta-alaninamides and derivatives as antidiabetics | PFIZER (US) | 1997-01-22 | — | — | CN | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5234917-A | Hypotensive agent, treatment of renal failure or glaucoma | SMITHKLINE BEECHAM CORPORATION | 1993-08-10 | — | — | US | disclosed |
| EP-0437103-A2 | Substituted 5-(alkyl)carboxamide imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-17 | — | — | EP | disclosed |
| US-4826855-A | Thieno pyridines and their use as anti-hypertensive agents | BOEHRINGER INGELHEIM KG (DE) | 1989-05-02 | — | — | US | disclosed |
| US-4766129-A | Pyrrolo[2,3-C]pyridines and their use as anti-hypertensive agents | BOEHRINGER INGELHEIM KG (DE) | 1988-08-23 | — | — | US | disclosed |
| US-4683238-A | 2,3,4,9-tetrahydro beta carboline derivatives, useful as antihypertensive agents | BOEHRINGER INGELHEIM KG (DE) | 1987-07-28 | — | — | US | disclosed |
| US-4652519-A | Bifunctional chelating agents and process for their production | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1987-03-24 | — | — | US | disclosed |
| US-4555511-A | Thieno [3,2,C]pyridines useful as antihypertensives | BOEHRINGER INGELHEIM KG (DE) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | LTA4H 3518/4885LNPEP 3395/4885ERAP2 1812/4885 |
| US-20250034112-A1 | IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | JAK2, JAK1, MCL1 | LTA4H 3624/4885LNPEP 3809/4885ERAP2 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.